Pre-Made Mirococept biosimilar, Recombinant Protein targeting C3b/C4b: Recombinant therapeutic protein for drug discovery and mechanism of action (MOA) research

Pre-Made Mirococept biosimilar, Recombinant Protein targeting C3b/C4b: Recombinant therapeutic protein is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Mirococept (APT070) is a highly effective complement inhibitor which is derived from human CR1 (CD35). It consists of three functional units: the terminal three domains of CR1 which contain its biological activities, a membrane-associating peptide and a membrane-inserting myristoyl group. The last two units permit the binding to and insertion into the cell membrane. Mirococept is unique in that it is engineered to bind to cell surfaces in bulk and can block the complement system at the C3 level. It does not inhibit proteases generally, and its action is restricted to the complement system.

Mirococept (APT070) is a recombinant complement inhibitor derived from human complement receptor type 1 (CR1, CD35). This complement inhibitory domains of CR1 (in APT070) contain C3b-binding sites that lead to dissociation and inactivation of C3b from the classical and alternative pathway convertases. Mirococept effectively blocks and reduces the generation of the activated form of C3, and thwarts the release of both C3a and C5a.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-913-1mg	1mg	3090
GMP-Bios-INN-913-10mg	10mg	Inquiry
GMP-Bios-INN-913-100mg	100mg	Inquiry
GMP-Bios-INN-913-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Mirococept biosimilar, Recombinant Protein targeting C3b/C4b: Recombinant therapeutic protein
INN Name	Mirococept
Target	C3b/CO3;C4b
Format	Recombinant Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Conjugate - CR1 (complement receptor type 1, C3b/C4b receptor, C3BR, Knops blood group, KN, CD35) 41-238_peptidyl- myristoylated
VD LC	Conjugate - CR1 (complement receptor type 1, C3b/C4b receptor, C3BR, Knops blood group, KN, CD35) 41-238_peptidyl- myristoylated
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	MRC, King's College (London UK)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0